ICUHealthcare · Biotechnology

ICU Stock Forecast: Seastar Medical Holding Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$3.54

+1.23% on the day

The 1 Wall Street analysts covering Seastar Medical Holding Corp. hold a median 12-month price target of $10 — +182.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$15.6M

Ticker Nerd rank

21 / 100

Median analyst target

$10

Analysts covering

Revenue$615K+82.0% y/y

Operating income−$3.8M

Net income−$3.7M

Free cash flow−$3.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+16.8%

+6.0%

YTD

+47.5%

−60.7%

From 52W high

−71.5%

From 52W low

+60.2%

$12

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ICU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seastar Medical Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Revisions

Accruals

Momentum

Quality

Volatility

Issuance

Value

Size (90): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ICU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $8Median $10High $12

The green dot is the last close — the median target sits +182.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
14 May 2026	Maxim Group	Maintains	Buy	$6.00 → $8.00
20 Apr 2023	Maxim Group	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICU appears on the weeks it earns a place.

Performance

ICU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Seastar Medical Holding Corp. returned −60.7% against +16.3% for the S&P 500, dividends included.

ICU vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Seastar Medical Holding Corp. (ICU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.6×
Price / sales: 9.1×
Price / book: 3.5×
EV / EBITDA: −0.7×

Growth & margins

Revenue growth (YoY): 82.0%
Earnings growth (YoY): 82.0%
Gross margin: 91.2%
Operating margin: −616.4%
Net margin: 95.7%

Returns & dividend

Return on equity: −356.9%
Return on assets: −102.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Seastar Medical Holding Corp. (ICU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Seastar Medical Holding Corp. has a market value of $15.6M and an enterprise value of $8.8M.
Revenue in the twelve months to 30 June 2026: $1.7M. The latest quarter grew 82.0% year on year.
Net income over the same four quarters: −$13.6M, a −795.5% net margin.
Diluted earnings per share, trailing twelve months: $−3.91.
Free cash flow in the twelve months to 30 June 2026: −$13.7M.
Shares outstanding: 4.3M.
Trailing P/E: −0.6×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Seastar Medical Holding Corp. employs 18 people — $95K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

ICU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ICUSeastar Medical Holding Corp.	$15.6M	21
TPSTTempest Therapeutics, Inc.	$15.5M	37
CNSYCerenome, Inc.	$15.4M	17
LSTALisata Therapeutics, Inc.	$15.3M	56
PASGPassage Bio, Inc.	$15.3M	43
DAREDaré Bioscience, Inc.	$15.2M	27
MBRXMoleculin Biotech, Inc.	$15.1M	25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seastar Medical Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ICU news & analysis

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

SeaStar Medical Holding Corporation announced that its Chief Executive Officer, Eric Schlorff, will participate in the HC Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City. The company is a commercial-stage healthcare company focused on treatments for critically ill patients facing organ failure.

Why it matters — The conference participation gives ICU watchers a scheduled opportunity for the company's CEO to present and address investors, serving as a notable corporate visibility and communication event.

SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

SeaStar Medical Holding Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.

Why it matters — Earnings call transcripts provide investors with direct insight into management's commentary on quarterly performance and strategic outlook.

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 12 Aug 2026positive

SeaStar Medical announced its second quarter 2026 financial results and business updates. The company added three top-rated children's hospitals to its QUELIMMUNE pediatric acute kidney injury (AKI) customer base, driving net revenue up 82% versus the second quarter of 2025.

Why it matters — An ICU watcher would care because the expansion of QUELIMMUNE into more pediatric hospitals signals growing adoption of the therapy for AKI in critically ill children.

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

GlobeNewsWire · 6 Aug 2026neutral

SeaStar Medical Holding Corporation announced that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and will host a webcast and conference call to discuss the results and business progress.

Why it matters — The scheduled earnings release and conference call give SeaStar Medical watchers a designated date to hear the company's latest financial results and business updates.

FAQ

Frequently asked questions about ICU stock

What is the ICU stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Seastar Medical Holding Corp. have a median 12-month price target of $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICU stock a buy right now?

Of the 1 analysts covering Seastar Medical Holding Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seastar Medical Holding Corp. 21 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICU?

As at 19 Sept 2026, Seastar Medical Holding Corp. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will ICU stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +182.5% from the last close, and Ticker Nerd's factor model ranks Seastar Medical Holding Corp. 21 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICU stock forecast for 2030?

No analyst covering Seastar Medical Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has ICU stock performed over the past year?

Seastar Medical Holding Corp. returned -60.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seastar Medical Holding Corp. do?

What is the latest news on ICU?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference". SeaStar Medical Holding Corporation announced that its Chief Executive Officer, Eric Schlorff, will participate in the HC Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City. The company is a commercial-stage healthcare company focused on treatments for critically ill patients facing organ failure.

Company

About Seastar Medical Holding Corp.

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation. The company’s current product portfolio includes QUELIMMUNE, an FDA-approved treatment for pediatric acute kidney injury associated with sepsis or septic condition requiring renal replacement therapy, along with additional SCD-based programs in adult kidney injury and other serious inflammatory indications. Based in Denver, Colorado, SeaStar Medical operates in the medical technology and specialty devices market, addressing unmet needs in hospital intensive care and renal replacement settings.

CEO Mr. Eric Schlorff · 18 employees · United States · https://seastarmedical.com